Table 4. Phenotype frequencies for combined controls, bladder cancer and melanoma patients.

	Controls n=208			Patients n=196/99				Melanoma n=91
TNF+488G	207	208	99.5%	194	196	99.0%		91	91	100%
TNF+488A	31	208	14.9%	55	196	28.1%	P=0.0012	13	91	14%	P=0.89
TNF−238G	206	208	99.0%	196	196	100.0%		91	91	100%
TNF−238A	21	208	10.1%	21	196	10.7%	P=0.84	8	91	8.80%	P=0.76
TNF−308G	203	208	97.6%	193	196	98.5%		90	91	99%
TNF−308A	69	208	33.2%	56	196	28.6%	P=0.32	34	91	37%	P=0.48
TNF−1032T	198	208	95.2%	97	99	98.0%		89	91	98%
TNF−1032C	79	208	38.0%	36	99	36.4%	P=0.78	35	91	38%	P=0.94
TNF−865C	205	208	98.6%	98	99	99.0%		89	91	98%
TNF−865A	59	208	28.4%	26	99	26.3%	P=0.70	27	91	30%	P=0.82
TNF−859C	206	208	99.0%	194	196	99.0%		91	91	100%
TNF−859T	30	208	14.4%	51	196	26.0%	P=0.0036	13	91	14%	P=0.98
TNF−380G	208	208	100.0%	99	99	100.0%		91	91	100%
TNF−380A	5	208	2.4%	0	99	0.0%	P=0.12	5	91	5%	P=0.17

The significant results TNF+488 and TNF−859 are highlighted with a grey background.